Agios Pharmaceuticals, Inc. (AGIO) News
Filter AGIO News Items
AGIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AGIO News Highlights
- AGIO's 30 day story count now stands at 2.
- Over the past 4 days, the trend for AGIO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AGIO are DEC.
Latest AGIO News From Around the Web
Below are the latest news stories about AGIOS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AGIO as an investment opportunity.
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo – – Improvements Observed in Annualized Rates of Sickle Cell Pain Crises, Markers of Hemolysis and Erythropoiesis in Participants Treated with Mitapivat – – Agios to Host Live and Webcast Investor Event on Dec. 11, 2023, at 7:00 a.m. Pacific Time – CAMBRIDGE, Mass., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular |
Agios Pharmaceuticals (NASDAQ:AGIO) shareholders have endured a 59% loss from investing in the stock five years agoWe think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly... |
Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia TreatmentData from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint. |
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy Volunteers Study – – Company Expects to Initiate Phase 2b Study in Mid-2024 – CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that clinical proof-of-concep |
Time To Worry? Analysts Just Downgraded Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) OutlookMarket forces rained on the parade of Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) shareholders today, when the analysts... |
Calculating The Fair Value Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Key Insights The projected fair value for Agios Pharmaceuticals is US$21.88 based on 2 Stage Free Cash Flow to Equity... |
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call TranscriptAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript November 2, 2023 Agios Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.64, expectations were $-1.69. Operator: Good day and thank you for standing by. Welcome to the Agios Pharmaceuticals Incorporated quarter three 2023 earnings conference call. At this time, all participants are in a listen-only […] |
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags SalesAgios' (AGIO) Q3 earnings beat estimates, but sales miss the same. |
Agios Pharmaceuticals Inc (AGIO) Reports Q3 2023 Earnings, Reveals 10% Increase in U.S. Net RevenueAgios Pharmaceuticals Inc (AGIO) announces Q3 2023 financial results and business highlights |
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advancement to Phase 3 Portion of RISE UP – – Agios to Highlight Additional Data on the Burden of Disease in Pyruvate Kinase (PK) Deficiency and Alpha- and Beta-Thalassemia – – New Preclinical Data for Novel PK Activator AG-946 Suggest Improvements in Ineffective Erythropoiesis in Model of Myelodysplastic S |